INSANE: Artiva | Rare Historical Photos

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics is ending development of AlloNK after two deaths in a Phase 2a autoimmune disease trial, cutting most of its workforce and reviewing strategic options.

Medical Daily · Oct 30

2 Small-Cap Stocks With Big Potential to Buy Under $30

These under-$30 stocks are betting on innovative therapies that could unlock massive long-term value.

Barchart · May 1

4 Biotech Stocks Lifting Off As Momentum Builds

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels. Here's a look at four stocks showing notable momentum gains.

Benzinga · Oct 21, 2025